amshespe, Author at 黑料网 Blood Research Center

In the NIH-funded 鈥楢merican Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT)鈥� trial, 黑料网 was one of 3 participating clinical centers to enroll patients with platelet transfusion-dependence due to therapy for hematologic malignancies. Between 2016 and 2020, 337 patients were randomized in a double blind fashion to tranexamic acid (TXA) or placebo. Ultimately, no benefit of …

Matthew Flick, PhD was recently awarded a NIH U01 grant, which is part of the Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC). This is an MPI award that Dr. Flick received with collaborators Bumsoo Han, PhD at Purdue University and Melissa Fishel, PhD at the Indiana University School of Medicine. The title of the …

Drs. Raj Kasthuri and Yara Park of the 黑料网 BRC, along with multiple alumni of the 黑料网 hematology and transfusion medicine fellowships, co-authored a multi-institutional investigation into the role of race in the response of TTP patients to rituximab that has been accepted for publication in Blood. The study included 645 TTP patients from …

photo of matthew karafin, smiling in a suit

The focus of the grant is to investigate red blood cell alloimmunization risk using the REDS-III databases. Red blood cell (RBC) alloimmunization is a leading cause of morbidity and mortality in transfusion and pregnancy settings, resulting in hemolytic reactions and other adverse sequelae such as hemolytic disease of the fetus and newborn. Alloimmunization occurs in …

Dr. Patrick Ellsworth has been awarded the聽Access to Insight 2022 Basic Research Grant, totaling 63,000 Euros! This was a competitive grant with international applicants. Dr. Ellsworth’s project is titled 鈥淢echanistic Investigation of Factor IX/IXa Synergy with Emicizumab鈥� and he will be working with Dr. Monroe here of the BRC and Dr. Maureane Hoffman at Duke …

Effective July 1, 2022, Dr. Alisa Wolberg began service as the new Chair of the Hemostasis, Thrombosis, Blood Cells, and Transfusion study section of the NHLBI. She will serve a 2-year term in this role. Congratulations, Dr. Wolberg!

“A gene therapy clinical trial for hemophilia shows promise and could be approved by the FDA later this year 鈥� a feat made possible, in part, by 黑料网-Chapel Hill鈥檚 70-year-old research program.” Click here to read the article.